Mechanism study of hNPC01 neural progenitor cell grafting therapy in a rat ischemic stroke model was published in Nature Communications
Hopstem Biotechnology at 2024 CASSS CGPT Symposium
Hopstem to Showcase hNPC01 Clinical Data at 2024 ASGCT Annual Meeting in Baltimore
hNPC01, human iPSC-derived human forebrain neural progenitor cell product of Hopstem Biotech has been granted clinical approval treating hemiplegia sequelae after chronic ischemic stroke by FDA
hNPC01, human iPSC-derived human forebrain neural progenitor cell product of Hopstem Biotech has been granted clinical approval treating hemiplegia sequelae after chronic ischemic stroke by CFDA
Join the leader of iPSC Cell Therapy!